Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Evaxion (NASDAQ: EVAX) will present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma at the ESMO Congress 2026 in Madrid, October 23-27, 2026. The third-year extension evaluates EVX-01 as stand-alone therapy in a subset of patients, offering insight into effects without anti-PD-1 combination.
According to Evaxion, prior two-year data from the same trial showed a 75% Objective Response Rate (12/16 patients), including four complete responses, 92% of patients still responding at two years with no relapses, tumor reduction in 15/16 patients, and EVX-01-induced immune responses in all patients, with 86% of targeted neoantigens generating specific T-cell responses.
Evaxion (NASDAQ: EVAX) reported new preclinical data from its cytomegalovirus (CMV) vaccine program EVX‑V1, presented in a poster at the International Herpesvirus Workshop 2026 in Montreal. EVX‑V1 is a next‑generation, multi‑component CMV vaccine program created with Evaxion’s AI‑Immunology™ platform.
The vaccine concept combines AI‑discovered T‑cell epitopes and novel B‑cell antigens with AI‑optimized versions of established structural B‑cell antigens, aiming at broader multi‑targeted immune coverage. According to Evaxion, the new data in CMV‑infected mice indicate potential to improve control of acute infection, latency and viral reactivation, complementing earlier preclinical findings of reduced viral infection and superior viral neutralization. The company highlights CMV as a major unmet need, particularly for immunocompromised individuals and infants, with no licensed vaccine currently available.
Evaxion (NASDAQ:EVAX) will present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal on July 12, 2026. EVX-V1 combines AI-discovered antigens with AI-optimized established CMV antigens to support broadly protective vaccine design.
Evaxion (NASDAQ: EVAX) announced that its AI-Immunology™ platform received the 2026 Prix Galien UK Award for Best digital health solution. The AI-driven platform is used to decode the human immune system and design vaccine candidates for cancer and infectious diseases.
The award, chosen by a committee of scientific leaders from 10 candidates, is Evaxion’s second recognition from the Galien Prix Foundation in less than a year.
Evaxion (NASDAQ: EVAX) reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia. Developed using its AI-Immunology platform, EVX-04 targets multiple endogenous retrovirus tumor antigens and shows correct expression, secretion, immune activation, and targeted cell-killing in preclinical models.
Evaxion (NASDAQ:EVAX) will present new preclinical data on its off-the-shelf AML vaccine EVX-04 at the EHA 2026 Congress in Stockholm on June 13, 2026. The functional characterization data mark a step towards clinical testing, with a clinical trial application planned for the second half of 2026.
Evaxion (NASDAQ: EVAX) reported Q1 2026 results and a business update on May 7, 2026. Key points: AI-Immunology™ achieved 86% vaccine target recognition for EVX-01; phase 2 one-year extension completed with three-year data expected H2 2026; new polio vaccine designs from Gates Foundation collaboration; cash $18.4M; runway into H2 2027.
Evaxion (NASDAQ: EVAX) will release a business update and first quarter 2026 financial results on May 7, 2026, before Nasdaq opening. Management will host a conference call and webcast on the same day at 14:30 CET / 08:30 EST. Registration is required to obtain dial-in numbers and a PIN.
The webcast will open 15 minutes early and a recording will be posted on the company website shortly after the event. Contact: Mads Kronborg, Vice President, Investor Relations & Communication.
Evaxion (NASDAQ: EVAX) announced on April 27, 2026 that Birgitte Rønø, previously Chief Scientific Officer, has been promoted to a dual role as Chief Scientific Officer and Chief Operating Officer. The change follows an internal management review to align organisation structure to maximise external engagement with partners and investors. Management composition otherwise remains: Helen Tayton-Martin, CEO; Thomas Schmidt, CFO; Andreas Mattsson, Chief AI Officer. Contact: Mads Kronborg, VP Investor Relations.
Evaxion (NASDAQ: EVAX) reported phase 2 EVX-01 data showing 86% of vaccine targets triggered tumor-specific immune responses and durable two-year vaccine-specific responses.
The trial tested EVX-01 with KEYTRUDA in advanced melanoma, reported a 75% objective response rate, and will present detailed results at AACR on April 22, 2026.